Magnasense/AegirBio UK Ltd. announces that Vasiliki Fragkou has officially stepped down from her position.
We would like to sincerely thank Vasiliki for her dedication and contributions during her time with us. Her efforts have been greatly appreciated, and she played an important role in advancing our mission and supporting our team.
We wish Vasiliki all the very best in her future endeavors and continued success in whatever path she chooses next.
For additional information, please contact:
Marco Witteveen, CEO, Magnasense AB
Email: ir@magnasense.com
The Company's Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se
About Magnasense AB
Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.
